Patents by Inventor Kean Hooi Ang

Kean Hooi Ang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11099172
    Abstract: The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agents with the ability to inhibit microglial activation in vivo in response to different ligands.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 24, 2021
    Assignees: The J. David Gladstone Insitutes, The Regents of the University of California
    Inventors: Katerina Akassoglou, Michelle Arkin, Kean-Hooi Ang, Anke Meyer-Franke, Christopher Wilson
  • Publication number: 20200157082
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Patent number: 10633370
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 28, 2020
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Health and Human Services, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Publication number: 20190375704
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: May 21, 2019
    Publication date: December 12, 2019
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 10343981
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20190064152
    Abstract: The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agents with the ability to inhibit microglial activation in vivo in response to different ligands.
    Type: Application
    Filed: April 2, 2018
    Publication date: February 28, 2019
    Inventors: Katerina Akassoglou, Michelle Arkin, Kean-Hooi Ang, Anke Meyer-Franke, Christopher Wilson
  • Publication number: 20180319778
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 8, 2018
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institute of Health, A Component of the U.S Department of Health and Human Services, The Regents of the University of California
    Inventors: Donna M. HURYN, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neilz, Kean-Hooi Ang, Cliffford Bryant, Stacie Bulfer
  • Publication number: 20180289682
    Abstract: Disclosed herein, inter alia, are compounds and methods useful for increasing stress resistance.
    Type: Application
    Filed: October 7, 2016
    Publication date: October 11, 2018
    Inventors: Cynthia Kenyon, Peichuan Zhang, James Cregg, Kean-Hooi Ang, Michelle Arkin
  • Publication number: 20170342020
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: June 5, 2017
    Publication date: November 30, 2017
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 9708247
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20170003280
    Abstract: The present invention provides cell-based assays, including high throughput cell-based assays, for identification of candidate therapeutic agent with no known agents with the ability to inhibit microglial activation in vivo in response to different ligands.
    Type: Application
    Filed: January 9, 2015
    Publication date: January 5, 2017
    Inventors: Katerina Akassoglou, Michelle Arkin, Kean-Hooi Ang, Anke Meyer-Franke, Christopher Wilson
  • Publication number: 20160096800
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: September 9, 2015
    Publication date: April 7, 2016
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 6143756
    Abstract: Manzamines, administered either intraperitoneally or orally, have been found to prolong survival and inhibit parasitemia in erythrocytic stage malaria. Thus, manzamines can be used for both prophylaxis and treatment. Manzamine A is a preferred compound for use in prophylaxis or treatment.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: November 7, 2000
    Assignee: National University of Singapore
    Inventors: Anna Ursula Kara, Tatsuo Higa, Michael Holmes, Kean Hooi Ang